Adult Malignant Glioma Therapeutics Market Report 2026

Adult Malignant Glioma Therapeutics Market Overview

• Adult Malignant Glioma Therapeutics market size has reached to $2.47 billion in 2025 • Expected to grow to $3.94 billion in 2030 at a compound annual growth rate (CAGR) of 9.9% • Growth Driver: Government Funding Catalyzing Advancements In Adult Malignant Glioma Therapeutics • Market Trend: Innovations In Small Molecule Targeted Degraders For Adult Malignant Glioma Therapeutics • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Adult Malignant Glioma Therapeutics Market?

An adult malignant glioma is a type of brain tumor that originates in the glial cells of the brain or spinal cord. Adult malignant glioma therapeutics refers to the various treatment options available for malignant gliomas in adults, aiming to improve quality of life and prolong survival. The main types of adult malignant glioma therapeutics are glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme (GBM) is an aggressive brain tumor characterized by rapid growth and the infiltration of adjacent brain tissue, typically without distant organ metastasis. The various therapies are chemotherapy, targeted therapy, radiotherapy, and others used in hospitals, specialty clinics, cancer and radiation therapy centers, and others.

What Is The Adult Malignant Glioma Therapeutics Market Growth Forecast?

The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.94 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to development of targeted molecular therapies, expansion of clinical trials for novel glioma treatments, increasing investment in precision oncology, rising collaborations between biotech and healthcare providers, adoption of advanced radiotherapy and combination therapy techniques. Major trends in the forecast period include increasing development of targeted glioma therapies, rising adoption of combination treatment approaches, expansion of experimental and personalized therapies, growing focus on improving patient quality of life, increased utilization of advanced radiotherapy techniques.

Global Adult Malignant Glioma Therapeutics Market Segmentation

1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types 2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies 3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users Subsegments: 1) By Glioblastoma Multiforme: Standard Treatments, Experimental Therapies 2) By Anaplastic Astrocytoma: Chemotherapy Options, Targeted Therapies 3) By Anaplastic Oligodendroglioma: Radiation Therapy, Combination Therapies 4) By Anaplastic Oligoastrocytoma: Surgical Interventions, Adjuvant Therapies 5) By Other Types: Rare Gliomas, Emerging Therapies

What Is The Driver Of The Adult Malignant Glioma Therapeutics Market?

Government funding to support brain cancer research is expected to propel the growth of the adult malignant glioma therapeutics market going forward. Government funding refers to the financial support provided by a government entity, whether at the federal, state, or local level, to various organizations, initiatives, projects, programs, or individuals. Government funding to support brain cancer research can be helpful for adult malignant glioma therapeutics by supporting the development of novel treatments, customized drug development, targeting pyrimidine synthesis, and orphan drug approval. For instance, in June 2023, the Australian Department of Health and Aged Care, an Australia-based government authority, initiated the Australian Brain Cancer Mission with a fund of $136.66 million to support research into brain cancer. The initiative aims to double the survival rates and thereby improve the quality of life of patients with brain cancer, including anaplastic astrocytoma. Therefore, government funding to support brain cancer research drives the adult malignant glioma therapeutics industry.

Key Players In The Global Adult Malignant Glioma Therapeutics Market

Major companies operating in the adult malignant glioma therapeutics market are Johnson & Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan plc, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genentech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

Global Adult Malignant Glioma Therapeutics Market Trends and Insights

Major companies operating in the adult malignant glioma therapeutics market are developing innovative products, such as small molecule targeted degraders, to provide reliable customer service. A small-molecule targeted degrader is a drug that uses small molecules to induce the degradation of specific proteins by targeting the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a Sweden-based precision oncology company, received orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17 to treat glioblastoma (GBM). It is a small-molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST that has been implicated in the pathogenesis of various cancers, including GBM. BEA-17 works by degrading LSD1 and CoREST, which leads to the reactivation of tumor suppressor genes and the inhibition of cancer cell growth.

What Are Latest Mergers And Acquisitions In The Adult Malignant Glioma Therapeutics Market?

In May 2024, Novartis, a Switzerland-based pharmaceutical company, acquired Mariana Oncology for $1 billion. This acquisition aims to strengthen Novartis's pipeline in radioligand therapies (RLTs) for various cancers, including potential applications for solid tumors such as gliomas. Mariana Oncology is a US-based preclinical-stage biotechnology company, providing therapeutics for gliomas.

Regional Outlook

North America was the largest region in the adult malignant glioma therapeutics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Adult Malignant Glioma Therapeutics Market?

The adult malignant glioma therapeutics market consists of revenues earned by entities by providing services such as resection, subtotal resection, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The adult malignant glioma therapeutics market consists of sales of temozolomide, bevacizumab, carmustine, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adult Malignant Glioma Therapeutics Market Report 2026?

The adult malignant glioma therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adult malignant glioma therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.